Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Antitope Ltd.. (1/24/13). "Press Release: Antitope Ltd., Announces Protein Deimmunisation Research Agreement with NeuroPhage Pharmaceuticals, Inc.". Cambridge.

Organisations Organisation Antitope Ltd.
  Group Abzena (Group)
  Organisation 2 NeuroPhage Pharmaceuticals Inc.
  Today Proclara Biosciences Inc.
  Group Proclara Biosciences Inc.
Products Product Composite Protein™ deimmunisation technology
  Product 2 therapeutic protein
Index term Index term NeuroPhage–Antitope: drug development services, 201301– supply application of Composite Protein deimmunisation techn for therapeutic protein developm
Persons Person Baker, Matthew (Matt) (Antitope 201301 CEO + Co-founder)
  Person 2 Butt, Neil (Iontas 201804 CBO before Abzena + Antitope)
     


Antitope Ltd., UK ("Antitope") today announced a Research Agreement with NeuroPhage Pharmaceuticals, Inc., USA ("NeuroPhage") for the generation of a therapeutic protein with reduced immunogenicity. Under the Agreement, Antitope will apply it's Composite Protein™ deimmunisation technology to a next generation treatment for neurodegenerative diseases.

"We are delighted to be working with such an innovative company as NeuroPhage," said Dr Matthew Baker, Chief Executive Officer and co-founder of Antitope, adding "This partnership utilises Antitope's expertise in engineering non-immunogenic proteins to complement NeuroPhage's innovations in developing novel therapeutics based on clearance of pathological protein aggregates."


About Antitope

Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope's proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ and Composite Protein™ technologies result in the generation of proteins and humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.

For more information, please visit www.antitope.co.uk.or contact:

Antitope Ltd.
Dr Neil Butt, Business Development Director
Tel: +44 (0)1223 496190
Emai: info@antitope.co.uk


About NeuroPhage Parmaceuticals, Inc.

NeuroPhage is a biotechnology company focusing on a unique disease-modifying approach for treating protein aggregation diseases. NeuroPhage was founded in 2007 by a team based in Cambridge, MA, USA, along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.

For more information, please visit www.neurophage.com or contact info@neurophage.com


Contact Us

Antitope Ltd
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

Telephone: +44(0) 1223 496190
Fax: +44(0) 1223 496191
Email: info@antitope.co.uk

Antitope Ltd (US)
5338 E Saguaro Place
Paradise Valley
AZ 85253
United States

Email: info@antitope.com

   
Record changed: 2018-07-07

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Abzena (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top